Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study | |
Song, Yuqin; Gao, Quanli; Zhang, Huilai; Fan, Lei; Zhou, Jianfeng; Zou, Dehui; Li, Wei; Yang, Haiyan; Liu, Ting; Wang, Quanshun | |
2018 | |
卷号 | 132 |
ISSN号 | 0006-4971 |
DOI | 10.1182/blood-2018-99-117848 |
URL标识 | 查看原文 |
收录类别 | SCIE |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6349062 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Song, Yuqin,Gao, Quanli,Zhang, Huilai,et al. Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study[J],2018,132. |
APA | Song, Yuqin.,Gao, Quanli.,Zhang, Huilai.,Fan, Lei.,Zhou, Jianfeng.,...&Zhu, Jun.(2018).Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study.,132. |
MLA | Song, Yuqin,et al."Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study".132(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论